Select country change
Shopping cart (0 , 0,00 ) Menu Search
Manufactured by BioVendor

Myostatin Human ELISA (Prodomain Specific)

  • Regulatory status:RUO
  • Type:Sandwich ELISA, Biotin-labelled antibody
  • Other names:Growth/differentiation factor 8, GDF-8, MSTN
  • Species:Human
Please select your region to see available products and prices.
Cat. No. Size Price


New RD191058200R 96 wells (1 kit)
PubMed Product Details
Technical Data

Type

Sandwich ELISA, Biotin-labelled antibody

Applications

Serum, Plasma

Storage/Expiration

Store the kit at 2–8°C. Under these conditions, the kit is stable until the expiration date (see label on the box).

Calibration Curve

Calibration Range

0.16 – 10 ng/ml

Limit of Detection

0.05 ng/ml

Intra-assay (Within-Run)

n = 8, CV = 2.5%

Inter-assay (Run-to-Run)

n = 6, CV = 9.5%

Spiking Recovery

98.1%

Dilutation Linearity

88.4%

Summary

Features

  • It is intended for research use only
  • The assay time is less than 3.5 hours
  • The kit measures total Myostatin Latent Complex and free Myostatin Prodomain in serum and plasma (EDTA, citrate, heparin)
  • Assay format is 96 wells
  • Quality Controls are human serum based
  • Standard is recombinant protein based
  • Components of the kit are provided ready to use, concentrated or lyophilized

Research topic

Cardiovascular disease, Energy metabolism and body weight regulation, Muscle growth and physiology regulation, Pulmonary diseases

Summary

Myostatin, also known as growth and differentiation factor 8 (GDF-8), belongs to the transforming growth factor β (TGF-β) superfamily of structurally related growth factors. Myostatin plays an essential role in regulating skeletal muscle growth and differentiation of tissues throughout the body and this function appears to be conserved across species.
Myostatin is expressed in human skeletal muscle as a biologically-inactive precursor protein (pre-promyostatin) consisting of an N-terminal signal peptide (23 amino acid residues), a propeptide domain (myostatin prodomain) which contains 243 amino acid residues, and a C-terminal domain containing 113 amino acids. Precursor protein (pre-promyostatin) forms a homodimer before proteolytic processing. After removal of the signal peptide, a furin protein convertase cleaves the promyostatin to generate myostatin propeptide and biologically active 12 kDa mature glycoprotein myostatin. The cleaved propeptide molecules remain non-covalently disulfide-linked to the mature C-terminal dimer forming the Latent Complex.
The native myostatin circulates in serum as a part of the latent complex. Follistatin-related gene (FLRG) product has been reported to be an additional protein bound to circulating myostatin. The myostatin propeptide is known to bind and inhibit myostatin in vitro. This interaction is relevant in vivo, with a majority (>70%) of myostatin in serum being bound to its propeptide. Two molecules of myostatin propeptide inhibit the biological activity of one GDF-8 homodimer.
Overexpression of GDF-8 propeptide, follistatin or activin type II results in enhanced muscle development and increased skeletal muscle growth. It has been shown that GDF-8 propeptide inhibits specific GDF-8 binding to L6 myoblast cells. Myostatin mutation was found in a child with muscle hypertrophy which provides strong evidence that myostatin plays a significant role in regulating muscle mass in humans. Myostatin promotes differentiation of multipotent mesenchymal cells into the adipogenic lineage and inhibits myogenesis. Studies have shown that myostatin could play an important role in cardiac development and physiology and has regulatory roles in fat metabolism. Myostatin is expressed in myocardium where it exerts anti-hypertrophic, but profibrotic, effects. Circulating and local myostatin is elevated in chronic heart failure and is an important player in cardiac cachexia. GDF-8 as a negative regulator of skeletal muscle mass has been implicated in several diseases involved in muscle wasting and cachexia. Circulating myostatin levels in male patients are elevated in chronic obstructive pulmonary disease (COPD) and the elevated myostatin levels are negatively correlated with total body skeletal muscle mass. Myostatin not only regulates the growth of myocytes but also directly regulates muscle fibroblasts. Myostatin stimulates proliferation of muscle fibroblasts and production of extracellular matrix proteins both in vitro and in vivo. GDF-8 itself or molecules that inhibit GDF-8 signalling may prove useful in the treatment of musculodegenerative states such as muscular dystrophy, neuromuscular diseases or cancer cachexia. Myostatin blockade offers a strategy for reversing muscle wasting in Duchenne's muscular dystrophy (DMD) without resorting to genetic manipulation. Latent TGFβ binding protein 4 (LTBP4) was identified as a genetic modifier of muscular dystrophy. It has been shown that myostatin forms a complex with LTBPand that overexpression of LTBP4 led to a decrease in myostatin levels. LTBP4 also interacts with TGFβ and GDF11, a protein highly related to myostatin. These data identify LTBP4 as a multi-TGFβ family ligand binding protein with the capacity to modify muscle disease through overexpression.
Serum and intramuscular concentrations of myostatin-immunoreactive protein are increased in HIV-infected men with weight loss compared with healthy men and correlate inversely with fat-free mass index. It has been demonstrated that increased expression of the myostatin gene is associated with weight loss in men with AIDS wasting syndrome.

References to Summary

References to Myostatin

  • Artaza JN, Bhasin S, Magee TR, Reisz-Porszasz S, Shen R, Groome NP, Meerasahib MF, Gonzalez-Cadavid NF. Myostatin inhibits myogenesis and promotes adipogenesis in C3H 10T(1/2) mesenchymal multipotent cells. Endocrinology. 2005 Aug;146 (8):3547-57
  • Gonzalez-Cadavid NF, Taylor WE, Yarasheski K, Sinha-Hikim I, Ma K, Ezzat S, Shen R, Lalani R, Asa S, Mamita M, Nair G, Arver S, Bhasin S. Organization of the human myostatin gene and expression in healthy men and HIV-infected men with muscle wasting. Proc Natl Acad Sci U S A. 1998 Dec 8;95 (25):14938-43
  • Hill JJ, Davies MV, Pearson AA, Wang JH, Hewick RM, Wolfman NM, Qiu Y. The myostatin propeptide and the follistatin-related gene are inhibitory binding proteins of myostatin in normal serum. J Biol Chem. 2002 Oct 25;277 (43):40735-41
  • Jiang MS, Liang LF, Wang S, Ratovitski T, Holmstrom J, Barker C, Stotish R. Characterization and identification of the inhibitory domain of GDF-8 propeptide. Biochem Biophys Res Commun. 2004 Mar 12;315 (3):525-31
  • Lee SJ, McPherron AC. Regulation of myostatin activity and muscle growth. Proc Natl Acad Sci U S A. 2001 Jul 31;98 (16):9306-11
  • McPherron AC, Lee SJ. Double muscling in cattle due to mutations in the myostatin gene. Proc Natl Acad Sci U S A. 1997 Nov 11;94 (23):12457-61
  • Sharma M, Kambadur R, Matthews KG, Somers WG, Devlin GP, Conaglen JV, Fowke PJ, Bass JJ. Myostatin, a transforming growth factor-beta superfamily member, is expressed in heart muscle and is upregulated in cardiomyocytes after infarct. J Cell Physiol. 1999 Jul;180 (1):1-9
  • Taylor WE, Bhasin S, Artaza J, Byhower F, Azam M, Willard DH Jr, Kull FC Jr, Gonzalez-Cadavid N. Myostatin inhibits cell proliferation and protein synthesis in C2C12 muscle cells. Am J Physiol Endocrinol Metab. 2001 Feb;280 (2):E221-8
  • Thies RS, Chen T, Davies MV, Tomkinson KN, Pearson AA, Shakey QA, Wolfman NM. GDF-8 propeptide binds to GDF-8 and antagonizes biological activity by inhibiting GDF-8 receptor binding. Growth Factors. 2001;18 (4):251-9
Related Products Documents